Preclinical models in chimeric antigen receptor–engineered T-cell therapy
EL Siegler, P Wang - Human gene therapy, 2018 - liebertpub.com
Cancer immunotherapy has enormous potential in inducing long-term remission in cancer
patients, and chimeric antigen receptor (CAR)-engineered T cells have been largely …
patients, and chimeric antigen receptor (CAR)-engineered T cells have been largely …
Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
EL Siegler, P Wang - Human Gene Therapy, 2018 - europepmc.org
Cancer immunotherapy has enormous potential in inducing long-term remission in cancer
patients, and chimeric antigen receptor (CAR)-engineered T cells have been largely …
patients, and chimeric antigen receptor (CAR)-engineered T cells have been largely …
[引用][C] Preclinical Models in Chimeric Antigen Receptor–Engineered T-Cell Therapy
EL Siegler, P Wang - Human Gene Therapy, 2018 - cir.nii.ac.jp
Preclinical Models in Chimeric Antigen Receptor–Engineered T-Cell Therapy | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
[PDF][PDF] Preclinical Models in Chimeric Antigen Receptor–Engineered T-Cell Therapy
EL Siegler, P Wang - researchgate.net
Cancer immunotherapy has enormous potential in inducing long-term remission in cancer
patients, and chimeric antigen receptor (CAR)-engineered T cells have been largely …
patients, and chimeric antigen receptor (CAR)-engineered T cells have been largely …
Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy
EL Siegler, P Wang - Human gene therapy, 2018 - pubmed.ncbi.nlm.nih.gov
Cancer immunotherapy has enormous potential in inducing long-term remission in cancer
patients, and chimeric antigen receptor (CAR)-engineered T cells have been largely …
patients, and chimeric antigen receptor (CAR)-engineered T cells have been largely …